肠道菌群与肺癌免疫治疗的研究进展  

Research Progress on Gut Microbiota and Immunotherapy of Lung Cancer

作　　者：谢欣悦 赵红[1] 

机构地区：[1]延安大学附属医院肿瘤科,陕西 延安

出　　处：《临床医学进展》2023年第8期12514-12521,共8页Advances in Clinical Medicine

摘　　要：肠道菌群与人体共同进化,通过代谢、炎症、免疫等方面参与维持人体健康。人类与微生物之间存在一定的动态平衡,但不当饮食、各种医疗措施打破这种平衡状态,导致菌群失调,继而引起各种疾病。肠道菌群在肿瘤诊断和治疗方面是目前的研究热点。在肺癌的治疗中,免疫疗法应用广泛且发挥了很好的作用,但不同人群对免疫治疗的疗效以及不良反应存在很大差异。大量研究表明肠道菌群与肺癌的发生发展以及免疫治疗均有关联。本文将对肺癌患者肠道菌群与免疫治疗的研究进展进行综述,探讨肠道菌群对于肺癌的发生、免疫治疗疗效、免疫相关不良事件的影响,以及目前能够通过干预肠道菌群增加免疫治疗疗效的方法。The gut microbiota has co-evolved with the human body and participates in maintaining human health through metabolism, inflammation, immunity, and other aspects. There is a certain dynamic balance between humans and microorganisms, but improper diet and various medical measures disrupt this equilibrium and lead to gut microbiota dysbiosis, which subsequently causes various diseases. Gut microbiota is a current research hotspot in tumor diagnosis and treatment. In the treatment of lung cancer, immunotherapy is widely used and has played a good role, but the efficacy and adverse effects of immunotherapy vary greatly among different populations. Numerous studies have shown that gut microbiota is associated with the development of lung cancer and immuno-therapy. In this paper, we review the current research on gut microbiota and immunotherapy in lung cancer patients, and discuss the effects of gut microbiota on lung cancer development, immu-notherapy efficacy and immune-related adverse events, as well as the current methods to increase the efficacy of immunotherapy through gut microbiota intervention.

关 键 词：肠道菌群 肺癌 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]